

## **Updated Entitlement Offer Timetable**

Wellnex Life Limited (ASX: **WNX**) (**Wellnex** or **Company**) refers to the Company's prospectus lodged with ASIC and ASX on 13 June 2023 (**Prospectus**), in connection with the Company's proposed Entitlement Offer, Initial Placement, Second Placement, and Shortfall Offer (together, the **Offers**).

The Company advises that the indicative timetable for Entitlement Offer, as set out in the Prospectus, has been amended as follows:

- the "Ex" Date for the Entitlement Offer is now **Friday, 16 June 2023**;
- the Record Date for the Entitlement Offer is now **Monday, 19 June 2023 at 7.00pm (AEST)**; and
- the opening date of the Entitlement Offer (and the date on which the Prospectus and application forms are sent to eligible shareholders) is now **Thursday, 22 June 2023**.

All other dates in the indicative timetable set out in the Prospectus remain unchanged.

The Company **attaches** an updated indicative timetable for the Offers, which incorporates the above changes.

**-ENDS-**

### **Further information:**

#### **Investor & Media Relations**

Sophie Bradley

Reach Markets

Email: [IR@reachmarkets.com.au](mailto:IR@reachmarkets.com.au)

Phone: 1300 805 795

#### **Financial Advisor**

Ryan Legudi

Salter Brothers

Email: [ryan.legudi@salterbrothers.com.au](mailto:ryan.legudi@salterbrothers.com.au)

Phone: 03 9258 2100

### **About Wellnex Life:**

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business that specialises in developing and licensing healthcare brands and products to bring to market. Listed in 2021, Wellnex has successfully launched and licensed cutting-edge brands in emerging specialty categories and has established key partnerships and agreements with leading companies in the Australian and global health space. Wellnex is focused on building a portfolio of brands and businesses that can improve the health of consumers, that will ultimately create value for shareholders.

To stay up to date with news & announcements, register your details on the [Wellnex Life investor portal](#).

## Indicative Timetable

Event	Date (2023)
Trading halt	Thursday, 18 May
Settlement of Initial Placement, issue of Tranche 1 Shares under Initial Placement	Friday, 19 May
Enter voluntary suspension	Monday, 22 May
Commencement of bookbuild for Second Placement	Wednesday, 24 May
Lodgement of Notice of General Meeting with ASX	Friday, 9 June
Lodgement of Prospectus with ASIC	Tuesday, 13 June
Lodgement of Prospectus and Appendix 3B with ASX	Tuesday, 13 June
"Ex" Date (date from which Shares commence trading with the entitlement to participate in the Entitlement Offer)	Friday, 16 June
Record Date to determine entitlements under Entitlement Offer	7.00pm (AEST) on Monday, 19 June
Prospectus and Application Forms sent to Eligible Shareholders and Company announces that this has occurred	Thursday, 22 June
Entitlement Offer opens	Thursday, 22 June
Last date to extend Entitlement Offer Closing Date	Friday, 7 July
Entitlement Offer Closing Date	5.00pm (AEST) Wednesday, 12 July
Shareholder meeting to seek approval under Listing Rule 7.1 for the issue of Attaching Options and Second Placement Shares	Thursday, 13 July
Issue of Attaching Options under Initial Placement, and lodgement of Appendix 3G	Friday 14 July
Announcement of Entitlement Offer results	Monday, 17 July
Issue of Entitlement Offer Shares, and lodgement of Appendix 2A	Wednesday, 19 July
Second Placement Offer Closing Date	5.00pm (AEST) Tuesday, 25 July
Issue of Tranche 2 Shares under Initial Placement, Second Placement Shares and Shortfall Shares under Entitlement Offer (if any), and lodgement of Appendix 2A	Tuesday, 25 July
Completion of Pain Away Transaction	By 31 July

*The above dates are indicative only and subject to change. The Company may vary these dates without notice, including whether to close an Offer early, extend an Offer, or accept late applications, either generally or in particular cases. Any extension of a closing date will have a consequential effect on the anticipated date for issue of new securities under the relevant Offer(s). The Directors also reserve the right not to proceed with the whole or part of the Offers at any time prior to allotment. In that event, the relevant application monies will be returned without interest. Investors who wish to submit an application and subscribe for securities under an Offer are encouraged to do so as soon as possible after the Offers open.*